Source: Pharamceutical Technology

Verastem: Verastem to divest Copiktra rights to Secura Bio for up to $381m

Biopharmaceutical company Verastem has signed a definitive agreement to divest the global commercial and development rights for Copiktra (duvelisib) to...Read More... The post Verastem to divest Copiktra rights to Secura Bio for up to $381m appeared first on Pharmaceutical Technology.

Read full article »

Top Competitors or Alternatives

Missing a competitor? Contribute!

Annual Revenue
Employees
Brian Stuglik's photo - CEO of Verastem

CEO

Brian Stuglik

CEO Approval Rating

66/100

Verastem is a biopharmaceutical company that researches, develops and commercializes novel therapeutics for the treatment of cancer. Read more